Sophisticated modeling techniques can be powerful tools for decision makers seeking to understand the effects of cancer control interventions on population trends in cancer incidence and mortality. Yet the proven value of such models in health policy is limited by legitimate concerns over lack of transparency of complex models and variability in published results from different groups. NCI's Cancer Intervention and Surveillance Modeling Network (CISNET) was created to promote collaboration between independent modeling groups investigating similar questions. By using the same sources of data for inputs and agreeing on uniform outcome measures, the variability in results reflects uncertainty in the effects of cancer control interventions rather than differences in design of the analysis. Further, by working together, the modeling groups can coherently explain the causes of variation. This proposal furthers the goals of CISNET by using comparative modeling approach to estimate the contributions of tobacco control and screening to reducing deaths from lung cancer. Over the next 5 years, major trials will report results on the efficacy of helical CT screening for lung cancer. The five CISNET models described in this proposal represent an existing infrastructure with which to synthesize these new data with existing data from observational and cohort studies and tumor registries. This group of models is poised to translate trial results into population-level effects and to project trends in lung cancer incidence and mortality if these policy interventions were adopted alone or in combination. We propose to disseminate our results in ways that will allow decision makers to prioritize one or more specific interventions to achieve the greatest reduction in lung cancer deaths.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-4 (M1))
Program Officer
Stedman, Margaret R
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Massachusetts General Hospital
United States
Zip Code
Gallaher, Jill; Babu, Aravind; Plevritis, Sylvia et al. (2014) Bridging population and tissue scale tumor dynamics: a new paradigm for understanding differences in tumor growth and metastatic disease. Cancer Res 74:426-35
Near, Aimee M; Blackman, Kenneth; Currie, Laura M et al. (2014) Sweden SimSmoke: the effect of tobacco control policies on smoking and snus prevalence and attributable deaths. Eur J Public Health 24:451-8
Levy, David; Rodríguez-Buño, Ricardo L; Hu, Teh-Wei et al. (2014) The potential effects of tobacco control in China: projections from the China SimSmoke simulation model. BMJ 348:g1134
Holford, Theodore R; Meza, Rafael; Warner, Kenneth E et al. (2014) Tobacco control and the reduction in smoking-related premature deaths in the United States, 1964-2012. JAMA 311:164-71
de Koning, Harry J; Meza, Rafael; Plevritis, Sylvia K et al. (2014) Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. Ann Intern Med 160:311-20
Meza, Rafael; ten Haaf, Kevin; Kong, Chung Yin et al. (2014) Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials. Cancer 120:1713-24
McMahon, Pamela M; Meza, Rafael; Plevritis, Sylvia K et al. (2014) Comparing benefits from many possible computed tomography lung cancer screening programs: extrapolating from the National Lung Screening Trial using comparative modeling. PLoS One 9:e99978
Holford, Theodore R; Levy, David T; McKay, Lisa A et al. (2014) Patterns of birth cohort-specific smoking histories, 1965-2009. Am J Prev Med 46:e31-7
Munshi, Vidit; McMahon, Pamela (2013) Importance of Smoking Cessation in a Lung Cancer Screening Program. Curr Surg Rep 1:
Tramontano, Angela C; Cipriano, Lauren E; Kong, Chung Yin et al. (2013) Microsimulation model predicts survival benefit of radiofrequency ablation and stereotactic body radiotherapy versus radiotherapy for treating inoperable stage I non-small cell lung cancer. AJR Am J Roentgenol 200:1020-7

Showing the most recent 10 out of 13 publications